The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFIRI plus 5 mg/kg of bevacizumab versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE Study).
Masato Nakamura
No relevant relationships to disclose
Hideyuki Mishima
No relevant relationships to disclose
Shigeyoshi Iwamoto
No relevant relationships to disclose
Takao Takahashi
No relevant relationships to disclose
Hiroshi Tamagawa
No relevant relationships to disclose
Yoshinori Munemoto
No relevant relationships to disclose
Taishi Hata
No relevant relationships to disclose
Tadamichi Denda
No relevant relationships to disclose
Yoshitaka Morita
No relevant relationships to disclose
Michio Inukai
No relevant relationships to disclose
Akihiko Murata
No relevant relationships to disclose
Katsuyuki Kunieda
No relevant relationships to disclose
Naoki Nagata
No relevant relationships to disclose
Yoshitaka Kurachi
No relevant relationships to disclose
Takashi Oshiro
No relevant relationships to disclose
Kenji Ina
No relevant relationships to disclose
Yuji Miyamoto
No relevant relationships to disclose
Tatsu Shimoyama
No relevant relationships to disclose
Koji Oba
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose